New drug study for people with relapsed or refractory T-cell lymphoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called TR115 against the standard treatment options for people with peripheral T-cell lymphoma that has come back or hasn't responded to previous treatments. The goal is to see if TR115 can help shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of lymphoma called peripheral T-cell lymphoma (including subtypes like PTCL-NOS, AITL, ALCL, or NKTCL).
- You must have had at least one prior treatment, and you must have tried a newer drug (like chidamide, pralatrexate, or brentuximab vedotin) or be unable to tolerate it.
- You must be 18 years or older.
- You must be in generally good health (able to do daily activities, with a performance status of 0 or 1).
- You must have at least one tumor that can be measured on a scan (at least 1.5 cm in a lymph node or 1.0 cm elsewhere).
- Your heart, liver, and kidney function must be within certain limits, and you must be willing to provide a tissue sample (either from a previous biopsy or a new one).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs, SHR2554 and liposomal mitoxantrone, as the first treatment for peripheral T-cell lymphoma (PTCL), a rare type of blood cancer. The goal is to see if this combination is safe and effective.
This trial tests a combination of two drugs (adebrelimab and SHR2554) for people with a type of lymphoma called T-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this combination can help shrink tumors or stop the cancer from growing.
This trial is testing several new drug combinations for people with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to find new options that may work better.
This trial tests a new experimental antibody therapy for people with certain types of peripheral T-cell lymphoma that have not responded to or have come back after prior treatment. The study aims to see if the treatment is safe and effective.
This trial tests a new combination of two pills—linperlisib and an EZH2 inhibitor—for people with a type of lymphoma called peripheral T-cell lymphoma (PTCL) that has come back or not responded to previous treatment. The goal is to see if this combination can help control the disease with manageable side effects.
This trial tests a new treatment using immune cells (CAR-NK) made from donated cord blood. These cells are designed to find and attack T-cell lymphoma that has come back or not responded to other treatments. The goal is to see if this approach is safe and effective.
Hear when a new PTCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.